Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 5.6% in Entrada Therapeutics, Inc.'s common stock as of March 31, 2025.

Janus Henderson Group PLC has filed an Amendment No. 9 to its Schedule 13G, reporting a 6.0% beneficial ownership stake in Amdocs Limited's Ordinary Shares as of March 31, 2025.

Janus Henderson Group PLC has filed an Amendment No. 7 to its Schedule 13G, disclosing a beneficial ownership of 6.1% of Globus Medical, Inc.'s Class A Common Stock as of March 31, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 16,530,028 shares, or 6.2%, of ARAMARK's Common Stock as of March 31, 2025.

Janus Henderson Group PLC has filed an Amendment No. 4 to Schedule 13G, reporting a beneficial ownership of 6.3% in Biohaven Ltd.'s common stock as of an event date of March 31, 2025.

Janus Henderson Group PLC and its subsidiary have filed an amended Schedule 13G, revealing beneficial ownership of 6.4% of ASURE SOFTWARE INC's Class A Common Stock as of March 31, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in SS&C Technologies Holdings, Inc. as of March 31, 2025.

Janus Henderson Group Plc has filed an amended Schedule 13G, reporting a 6.9% passive beneficial ownership stake in Flex Ltd., totaling 26,312,378 ordinary shares.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 7.3% beneficial ownership stake in IDEAYA Biosciences, Inc. as of March 31, 2025, held for passive investment purposes.

Janus Henderson Group plc has filed an amended Schedule 13G, revealing a beneficial ownership of 7.4% in OSI Systems, Inc.'s common stock as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a 7.7% beneficial ownership stake in JANUX Therapeutics, Inc. common stock.

Janus Henderson Group plc has filed an Amendment No. 5 to its Schedule 13G, disclosing a beneficial ownership of 8.3% in Ziff Davis, Inc. common stock as of March 31, 2025.

Janus Henderson Group PLC and its subsidiary, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed beneficial ownership stakes in Larimar Therapeutics, Inc., as detailed in a recent Schedule 13G filing.

Janus Henderson Group PLC has filed an Amendment No. 9 to its Schedule 13G, reaffirming its passive beneficial ownership of 8.9% of Akero Therapeutics, Inc.'s Ordinary Shares as of March 31, 2025.

Janus Henderson Group PLC and its affiliate, Janus Henderson Contrarian Fund, have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.1% in Surgery Partners, Inc. as of March 31, 2025.

Investment manager Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 9.2% beneficial ownership stake in Dyne Therapeutics Inc.'s common stock.

Janus Henderson Group PLC, an investment adviser and parent holding company, has disclosed a 9.5% beneficial ownership stake in Lantheus Holdings, Inc. as of March 31, 2025, held for investment purposes.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Avidity Biosciences, Inc. as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 10.0% beneficial ownership stake in Madrigal Pharmaceuticals, Inc. as of March 31, 2025.

Janus Henderson Group PLC and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 10.3% in WEX, Inc.'s common stock as of March 31, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, revealing a beneficial ownership of 6.4% in Liberty Media Corporation's Series C Liberty Formula One Common Stock.

Janus Henderson Group PLC has filed an amended Schedule 13G, confirming its beneficial ownership of 10.5% of Ardelyx, Inc.'s common stock as of March 31, 2025.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have reported a combined beneficial ownership of 10.5% in Protara Therapeutics, Inc. as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a beneficial ownership of 11.2% of Soleno Therapeutics, Inc.'s common stock as of March 31, 2025.

Janus Henderson Group plc, along with its affiliates, has filed an amended Schedule 13G, reporting a beneficial ownership of 12.8% in Consensus Cloud Solutions, Inc. as of March 31, 2025.

Janus Henderson Group plc and its affiliate, Janus Henderson Contrarian Fund, have disclosed a continued beneficial ownership of 6.6% in The Beauty Health Company's common stock.

Janus Henderson Group PLC, along with its subsidiary Janus Henderson Enterprise Fund, has filed an amended Schedule 13G, reaffirming its substantial beneficial ownership in Cimpress PLC.

Janus Henderson Group plc and its affiliate have reported a combined beneficial ownership of 13.7% in LEXEO Therapeutics, Inc., totaling 4,557,920 common shares as of March 31, 2025.

Janus Henderson Group PLC has filed an Amendment No. 6 to its Schedule 13G, disclosing a beneficial ownership of 14.0% in 89BIO, INC. common stock as of March 31, 2025.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have filed an amendment to their Schedule 13G, disclosing continued beneficial ownership of 14.1% of Avadel Pharmaceuticals PLC's common stock as of March 31, 2025.